Table 3.
Time point** | Study period | |||||||
---|---|---|---|---|---|---|---|---|
Enrollment, May 20171 | Allocation, March 2018 | Post-allocation | Close-out, May 2020 | |||||
0w | 6w | 10w | t4 | etc. | ||||
Enrollment: | ||||||||
Eligibility screen | X | |||||||
Informed consent | X | |||||||
Allocation | X | |||||||
Interventions: | ||||||||
Combination (ACAT) group | X | X | X | |||||
TAU group | X | X | X | |||||
Assessments: | ||||||||
Socioeconomic and demographic data | X | X | X | X | X | |||
Patients: AKQ-C, DSRS-C, BACEv3, EEG | X | X | X | X | X | |||
Parents: AKQ-P, SDQ, Vineland-2, Bace-v3, GHQ-12, EEG | X | X | X | X | X |
AKQ-C Autism Knowledge Quiz-Child, DSRS-C Depression Self-Rating Scale for Children, BACEv3 Barriers to Access to Care Evaluation scale version 3, EEG electroencephalogram, AKQ-P Autism Knowledge Quiz-Parents, SDQ Strengths and Difficulties Questionnaire, GHQ-12 General Health Questionnaire